{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:55:27Z","timestamp":1787500527022,"version":"build-2736575974"},"reference-count":17,"publisher":"BMJ","issue":"7","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2026,5,28]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>Immune checkpoint inhibitors, a first-line treatment of metastatic melanoma and other cancers, improve survival but commonly cause immune-related cutaneous adverse events. Early recognition and classification of these adverse events are important for effective management. We present a case of an elderly man with metastatic melanoma who developed a widespread, pruritic grade 3\/4 eczematous reaction to pembrolizumab, significantly impacting his quality of life. Following cessation of the pembrolizumab, systemic steroids led to minimal response alongside adverse cushingoid effects. Consequently, immunomodulatory methotrexate treatment was introduced, leading to significant improvement within 3 months. Dry, atrophic skin and purpuric patches secondary to long-term steroid use were noted, so prednisolone was tapered. At 6 months, his skin rash cleared, so methotrexate was discontinued. Importantly, his melanoma remained in remission. This case highlights the importance of a multidisciplinary, stratified approach to the management of immunotherapy-related side effects and the early introduction of steroid-sparing agents to optimise patient care.<\/jats:p>","DOI":"10.1136\/bcr-2025-270207","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T10:35:18Z","timestamp":1783593318000},"page":"e270207","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Pembrolizumab-induced severe eczematous dermatitis and the use of methotrexate as a steroid-sparing agent"],"prefix":"10.1136","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2164-721X","authenticated-orcid":false,"given":"Sara Lupita","family":"O\u2019Kelly","sequence":"first","affiliation":[{"name":"Dermatology, East Kent Hospitals University NHS Foundation Trust, Canterbury, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor M","family":"Deane","sequence":"additional","affiliation":[{"name":"East Kent Hospitals University NHS Foundation Trust, Canterbury, UK"},{"name":"Oxford University Hospitals NHS Foundation Trust, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saul Maxim","family":"Halpern","sequence":"additional","affiliation":[{"name":"Dermatology, Medway NHS Foundation Trust, Gillingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"2026070903350879000_19.7.e270207.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"2026070903350879000_19.7.e270207.2","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1080\/21678707.2016.1191348","article-title":"Pembrolizumab for the treatment of advanced melanoma","volume":"4","author":"Burns","year":"2016","journal-title":"Expert Opin Orphan Drugs"},{"key":"2026070903350879000_19.7.e270207.3","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1002\/cncr.32160","article-title":"Changes in population-level survival for advanced solid malignancies with new treatment options in the second decade of the 21st century","volume":"125","author":"Pulte","year":"2019","journal-title":"Cancer"},{"key":"2026070903350879000_19.7.e270207.4","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","article-title":"Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression","volume":"151","author":"Sanlorenzo","year":"2015","journal-title":"JAMA Dermatol"},{"key":"2026070903350879000_19.7.e270207.5","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15072084","article-title":"Cutaneous Adverse Reactions of Immunotherapy in Patients with Advanced Melanoma","volume":"15","author":"Nikolaou","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026070903350879000_19.7.e270207.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001"},{"key":"2026070903350879000_19.7.e270207.7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacig.2024.100346","article-title":"Distinguishing DRESS syndrome from drug rash and eosinophilia: Beyond RegiSCAR criteria","volume":"3","author":"Thompson","year":"2024","journal-title":"J Allergy Clin Immunol Glob"},{"key":"2026070903350879000_19.7.e270207.8","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1080\/21645515.2016.1199310","article-title":"Pembrolizumab (Keytruda)","volume":"12","author":"Kwok","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"2026070903350879000_19.7.e270207.9","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239"},{"key":"2026070903350879000_19.7.e270207.10","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jaad.2021.03.094","article-title":"Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis","volume":"86","author":"Wongvibulsin","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2026070903350879000_19.7.e270207.11","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/jvc2.27","article-title":"Skin manifestations associated with checkpoint inhibitors","volume":"1","author":"Nazzaro","year":"2022","journal-title":"JEADV Clinical Practice"},{"key":"2026070903350879000_19.7.e270207.12","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003066","article-title":"Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy","volume":"9","author":"Halle","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026070903350879000_19.7.e270207.13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053745","article-title":"The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network","volume":"8","author":"Voskens","year":"2013","journal-title":"PLoS One"},{"key":"2026070903350879000_19.7.e270207.14","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1200\/JCO.2001.19.15.3477","article-title":"Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma","volume":"19","author":"Phan","year":"2001","journal-title":"J Clin Oncol"},{"key":"2026070903350879000_19.7.e270207.15","doi-asserted-by":"crossref","DOI":"10.5070\/D3265048774","article-title":"Resolution of pembrolizumab-associated lichenoid dermatitis with a single dose of methotrexate","volume":"26","author":"Varma","year":"2020","journal-title":"Dermatol Online J"},{"key":"2026070903350879000_19.7.e270207.16","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx642"},{"key":"2026070903350879000_19.7.e270207.17","doi-asserted-by":"crossref","unstructured":"Haanen J , Ernstoff M , Wang Y , et al . Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events. J Immunother Cancer 2020. doi:10.1136\/jitc-2020-000604","DOI":"10.1136\/jitc-2020-000604"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2025-270207","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T10:35:20Z","timestamp":1783593320000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2025-270207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":17,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,9]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/bcr-2025-270207"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2025-270207","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}